Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups?

doi:10.3748/wjg.v27.i24.3429

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 24

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4640)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

370

WORD

101

HTML

2514

Figures (1-2)

371

Tables (1-1)

267

Sum=3623

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

365

Download

652

Sum=1017

Jun 28, 2021 (publication date) through Nov 14, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Opinion Review

World J Gastroenterol. Jun 28, 2021; 27(24): 3429-3439
Published online Jun 28, 2021. doi: 10.3748/wjg.v27.i24.3429

Full Size Figure Download Figure

Figure 2 Sequencing systemic therapies in real-world setting. Note: These recommendations should be individualized for each patient. ADA: Anti-drug antibodies; AFP: Alpha-fetoprotein; Atezo + Bev: Atezolizumab + bevacizumab; CP: Child-Pugh; LT: Liver transplantation; mPVT: Main portal vein thrombosis; SOR: Sorafenib.

Citation: Piñero F, da Fonseca LG. Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups? World J Gastroenterol 2021; 27(24): 3429-3439
URL: https://www.wjgnet.com/1007-9327/full/v27/i24/3429.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i24.3429